rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ESLA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Estrella Immunopharma appoints new CEO and reshapes board

      Detailed price information for Estrella Immunopharma Inc (ESLA-Q) from The Globe and Mail including charting and trades.

      Oct 30The Globe and MailESLA
      Estrella Immunopharma names Cynthia Pussinen as CEO and board chair
      Oct 29Investing.comESLA
      Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
      Oct 26Yahoo FinanceESLA
      Estrella Immunopharma Shares Rise 17.91% After Hours - Estrella Immunopharma (NASDAQ:ESLA)
      Oct 22BenzingaESLA
      Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
      Oct 15Yahoo FinanceESLA
      Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
      Oct 14Yahoo FinanceESLA
      12 Health Care Stocks Moving In Friday's Pre-Market Session - Humana (NYSE:HUM), XORTX Therapeutics (NASD
      Oct 9BenzingaESLAHUM
      ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

      By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following

      Aug 26Yahoo FinanceESLA

      This is the newest page. Registered accounts read further back.